BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer.
Alan Coates, M.D., clinical professor in the School of Public Health at the University of Sydney in Australia, speaking at the 2008 San Antonio Breast Cancer Symposium
